C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Completed · Phase 2

Conditions studied: Prostate Cancer, Prostate Adenocarcinoma

In brief

Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. This clinical trial is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments.

Key facts

Study ID

NCT01530269

Run by

Phoenix Molecular Imaging

People needed

300

Starts

2012-04-01

Expected to finish

2019-01-01

Last updated by the study team

2019-03-07

Who can join

Age: 18 and older, up to 90. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male patients will be studied who have prostate cancer:
• Diagnosed with prostate adenocarcinoma
• Has completed conventional staging examinations, including histologic evaluation with Gleason score, CT scan of the abdomen and pelvis, and whole-body bone scintigraphy Candidate for curative prostatectomy OR curative radiotherapy OR staging lymphadenectomy prior to surgery
• Deemed to be at intermediate or high risk for recurrence or metastatic disease after initial curative treatment, as defined by of one of the following:
• Gleason score >= 7 or PSA >= 10
• Gleason score < 7 or PSA <10 ng/mL with positive surgical margins, biopsy proven or suspected regional nodal involvement or conventional imaging showing limited metastatic disease that may be amenable to directed radiotherapy
• Rising or non-responding PSA

You may not qualify if…

• < 18 years old
• claustrophobic patients

Where it is running

• Phoenix Molecular Imaging — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.